877 related articles for article (PubMed ID: 22120095)
1. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
[TBL] [Abstract][Full Text] [Related]
2. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
[TBL] [Abstract][Full Text] [Related]
4. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
Goldsmith SR; Gilbertson DT; Mackedanz SA; Swan SK
J Card Fail; 2011 Dec; 17(12):982-9. PubMed ID: 22123359
[TBL] [Abstract][Full Text] [Related]
5. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
6. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
7. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
9. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
Shoaf SE; Bramer SL; Bricmont P; Zimmer CA
J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
[TBL] [Abstract][Full Text] [Related]
12. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.
Watanabe K; Dohi K; Sugimoto T; Yamada T; Sato Y; Ichikawa K; Sugiura E; Kumagai N; Nakamori S; Nakajima H; Hoshino K; Machida H; Okamoto S; Onishi K; Nakamura M; Nobori T; Ito M
J Cardiol; 2012 Dec; 60(6):462-9. PubMed ID: 23068288
[TBL] [Abstract][Full Text] [Related]
14. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M
Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439
[TBL] [Abstract][Full Text] [Related]
15. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.
Naitoh M; Suzuki H; Murakami M; Matsumoto A; Arakawa K; Ichihara A; Nakamoto H; Oka K; Yamamura Y; Saruta T
Am J Physiol; 1994 Dec; 267(6 Pt 2):H2245-54. PubMed ID: 7810724
[TBL] [Abstract][Full Text] [Related]
16. Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure.
Starklint J; Bech JN; Nyvad O; Jensen P; Pedersen EB
Scand J Clin Lab Invest; 2006; 66(1):55-66. PubMed ID: 16464787
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
Matsuzaki M; Hori M; Izumi T; Fukunami M;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
[TBL] [Abstract][Full Text] [Related]
18. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
[TBL] [Abstract][Full Text] [Related]
20. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
